Business
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patientsPumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levelsData highlight the potential of pumitamig for patients wit
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"BioNTech SE","displaySize":"","headline":null,"caption":"BioNTech SE","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":33,"url":"https://media.zenfs.com/en/globenewswire.com/333ed4c7a82ed16ca3684c6fccef28ab"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CitAaObWfrAtVDjrB2dw4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/333ed4c7a82ed16ca3684c6fccef28ab","width":300,"height":33}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for investigational therapy pumitamig (BNT327/BMS986545) plus chemotherapy in first- and second-line patients","length":243,"tagName":"p"}]},{"val":[{"type":"text","content":"Pumitamig plus chemotherapy achieved confirmed objective response rate (cORR) of 61.5%, unconfirmed ORR (uORR) of 71.8% and disease control rate (DCR) of 92.3% irrespective of PD-L1 expression levels","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Data highlight the potential of pumitamig for patients with TNBC, including PD-L1 low or negative (CPS<10) TNBC which has limited treatment options and high unmet need","length":170,"tagName":"p"}]},{"val":[{"type":"text","content":"Data are consistent with the previously reported data from the 1L TNBC Phase 1b/2 trial conducted in China and confirm dose selection for the pivotal Phase 3 ROSETTA BREAST-01 trial ","length":181,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":793,"olType":false},{"type":"text","content":"MAINZ, Germany, and PRINCETON, USA, December 9, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced the first interim data from a global randomized Phase 2 trial (NCT06449222) evaluating pumitamig (BNT327/BMS986545), an investigational bispecific antibody targeting PD-L1 and VEGF-A, plus chemotherapy in patients with locally advanced/metastatic triple-negative breast cancer (“TNBC”) irrespective of PD-L1 expression levels.","length":488,"tagName":"p"},{"type":"text","content":"The data showed encouraging anti-tumor responses and a manageable safety profile for pumitamig plus chemotherapy in first-line and second-line treatment setting. The d...